Клітинна фармакодинаміка та фармакокінетика антибіотиків: сучасні погляди та перспективи

Клітинна фармакодинаміка та фармакокінетика антибіотиків: сучасні погляди та перспективи

Список літератури

Умовні позначення літературних джерел:
•• – джерела виняткового інтересу
• – джерела спеціального інтересу

  1. Bosso JA: The antimicrobial armamentarium: Evaluating current and future treatment options. Pharmacotherapy (2005) 25(10 Pt 2):55S-62S.
  2. Amsden GW, Ballow CH, Bertino JSJ: Pharmacokinetics and pharmacodynamics of anti-infective agents. In: Principles and Practice of Infectious Diseases. Mandell GL, Bennet JE, Dolin R (Eds), Churchill Livingstone, Philadelphia, PA, USA (2000):253-261.
  3. Andes D, Anon J, Jacobs MR, Craig WA: Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med (2004) 24(2):477-502.
  4. Andes D, Craig WA: Understanding pharmacokinetics and pharmacodynamics: Application to the antimicrobial formulary decision process. In: Antibiotic Optimization: Concepts and Strategies in Clinical Practice. Owens RC Jr, Ambrose PG, Nightingale CH (Eds), Marcel Dekker, New York, NY, USA (2005):65-88.
  5. Craig WA: Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 26(1):1-10.
  6. Craig WA: Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides and linezolid. Infect Dis Clin North Am (2003) 17(3):479-501.
  7. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL: Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: An update. J Antimicrob Chemother (2005) 55(5):601-607.
    •• Містить огляд термінології, що використовується в області PK/PD антибіотиків.
  8. McKinnon PS, Davis SL: Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol Infect Dis (2004) 23(4):271-288.
  9. Barger A, Fuhst C, Wiedemann B: Pharmacological indices in antibiotic therapy. J Antimicrob Chemother (2003) 52(6):893-898.
  10. Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM: Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Am (2003) 17(3):615-634.
    •• Містить огляд клітинної фармакодинаміки антибіотиків.
  11. Hackstadt T: The diverse habitats of obligate intracellular parasites. Curr Opin Microbiol (1998) 1(1):82-87.
  12. Young D, Hussell T, Dougan G: Chronic bacterial infections: Living with unwanted guests. Nat Immunol (2002) 3(11):1026-1032.
  13. Valentin-Weigand P: Intracellular invasion and persistence: Survival strategies of Streptococcus suis and Mycobacterium avium ssp paratuberculosis. Berl Munch Tierarztl Wochenschr (2004) 117(11-12):459-463.
  14. Cosma CL, Sherman DR, Ramakrishnan L: The secret lives of the pathogenic mycobacteria. Annu Rev Microbiol (2003) 57:641-676.
  15. Hammerschlag MR: The intracellular life of chlamydiae. Semin Pediatr Infect Dis (2002) 13(4):239-248.
  16. Clement S, Vaudaux P, Francois P, Schrenzel J, Huggler E, Kampf S, Chaponnier C, Lew D, Lacroix JS: Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosinusitis. J Infect Dis (2005) 192(6):1023-1028.
  17. Ellington JK, Harris M, Webb L, Smith B, Smith T, Tan K, Hudson M: Intracellular Staphylococcus aureus. A mechanism for the indolence of osteomyelitis. J Bone Joint Surg Br (2003) 85(6):918-921.
  18. Brouillette E, Grondin G, Shkreta L, Lacasse P, Talbot BG: In vivo and in vitro demonstration that Staphylococcus aureus is an intracellular pathogen in the presence or absence of fibronectinbinding proteins. Microb Pathog (2003) 35(4):159-168.
  19. Gresham HD, Lowrance JH, Caver TE, Wilson BS, Cheung AL, Lindberg FP: Survival of Staphylococcus aureus inside neutrophils contributes to infection. J Immunol (2000) 164(7):3713-3722.
  20. Marouni MJ, Barzilai A, Keller N, Rubinstein E, Sela S: Intracellular survival of persistent group A streptococci in cultured epithelial cells. Int J Med Microbiol (2004) 294(1):27-33.
  21. Mandell GL: Uptake, transport, delivery and intracellular activity of antimicrobial agents. Pharmacotherapy (2005) 25(12):130S-133S.
    •• Містить огляд клітинної фармакокінетики антибіотиків.
  22. Blaser MJ, Atherton JC: Helicobacter pylori persistence: Biology and disease. J Clin Invest (2004) 113(3):321-333.
  23. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ: Intracellular bacterial biofilm-like pods in urinary tract infections. Science (2003) 301(5629):105-107.
  24. Anderson GG, Dodson KW, Hooton TM, Hultgren SJ: Intracellular bacterial communities of uropathogenic Escherichia coli in urinary tract pathogenesis. Trends Microbiol (2004) 12(9):424-430.
  25. Butts JD: Intracellular concentrations of antibacterial agents and related clinical implications. Clin Pharmacokinet (1994) 27(1):63-84.
  26. Bakker-Woudenberg IA, van Vianen W, van Soolingen D, Verbrugh HA, van Agtmael MA: Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase and their use in combination. Antimicrob Agents Chemother (2005) 49(6):2387-2398.
  27. Nuermberger E, Grosset J: Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis (2004) 23(4):243-255.
  28. Brouillette E, Martinez A, Boyll BJ, Allen NE, Malouin F: Persistence of a Staphylococcus aureus small-colony variant under antibiotic pressure in vivo. FEMS Immunol Med Microbiol (2004) 41(1):35-41.
  29. Kerrn MB, Struve C, Blom J, Frimodt-Moller N, Krogfelt KA: Intracellular persistence of Escherichia coli in urinary bladders from mecillinam-treated mice. J Antimicrob Chemother (2005) 55(3):383-386.
    • Стійкість внутрішньоклітинної E. coli при невідповідному дозуванні β-лактамів in vivo.
  30. Krut O, Sommer H, Kronke M: Antibiotic-induced persistence of cytotoxic Staphylococcus aureus in non-phagocytic cells. J Antimicrob Chemother (2004) 53(2):167-173.
  31. Steinberg TH: Cellular transport of drugs. Clin Infect Dis (1994) 19(5):916-921.
  32. Tulkens PM: Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis (1991) 10(2):100-106.
  33. Rang HP, Dale MM, Ritter JM, Moore PK: Absorption and distribution of drugs. In: Pharmacology. Churchill Livingstone Inc, Edinburgh, Scotland (2003):91-105.
  34. Wilkinson GR: Pharmacokinetics: The dynamics of drug absorption, distribution and elimination. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. Hardman JG, Limbird LE (Eds), McGraw-Hill Publishing Co, New York, NY, USA (2001):3-30.
  35. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F: Commentary. Lysosomotropic agents. Biochem Pharmacol (1974) 23(18):2495-2531.
  36. Laufen H, Wildfeuer A, Rader K: Uptake of antimicrobial agents by human polymorphonuclear leucocytes. Arzneimittel-Forsch (1985) 35(7):1097-1099.
  37. Renard C, Vanderhaeghe HJ, Claes PJ, Zenebergh A, Tulkens PM: Influence of conversion of penicillin G into a basic derivative on its accumulation and subcellular localization in cultured macrophages. Antimicrob Agents Chemother (1987) 31(3):410-416.
  38. Chanteux H, Mingeot-Leclercq MP, Sonveaux E, Van Bambeke F, Tulkens PM: Intracellular accumulation and activity of ampicillin used as free drug and as its phthalimidomethyl or pivaloyloxymethyl ester (pivampicillin) against Listeria monocytogenes in J774 macrophages. J Antimicrob Chemother (2003) 52(4):610-615.
  39. Dorian M, Grellet J, Saux MC: Uptake of fluoroquinolones in human monocytes isolated from peripheral blood. J Pharm Pharmacol (1998) 50(7):783-788.
  40. Michot JM, Seral C, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM: Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin and moxifloxacin) in J774 macrophages. Antimicrob Agents Chemother (2005) 49(6):2429-2437.
    • Описано порівняльне дослідження накопичення та ефлюксу хінолонів у макрофагах.
  41. Carlier MB, Scorneaux B, Zenebergh A, Desnottes JF, Tulkens PM: Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J Antimicrob Chemother (1990) 26(Suppl B):27-39.
  42. Rispal P, Grellet J, Celerier C, Breilh D, Dorian M, Pellegrin JL, Saux MC, Leng B: Comparative uptake of sparfloxacin and ciprofloxacin into human THP 1 monocytic cells. Arzneimittel-Forsch (1996) 46(3):316-319.
  43. Amsden GW: Advanced-generation macrolides: Tissue-directed antibiotics. Int J Antimicrob Agents (2001) 18(Suppl 1):S11-S15.
  44. Carlier MB, Zenebergh A, Tulkens PM: Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J Antimicrob Chemother (1987) 20(Suppl B):47-56.
  45. Carlier MB, Garcia-Luque I, Montenez JP, Tulkens PM, Piret J: Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. Int J Tissue React (1994) 16(5-6):211-220.
  46. Montenez JP, Van Bambeke F, Piret J, Brasseur R, Tulkens PM, Mingeot-Leclercq MP: Interactions of macrolide antibiotics (erythromycin A, roxithromycin, erythromycylamine [dirithromycin] and azithromycin) with phospholipids: Computer-aided conformational analysis and studies on acellular and cell culture models. Toxicol Appl Pharmacol (1999) 156(2):129-140.
  47. Pascual A, Ballesta S, Garcia I, Perea EJ: Uptake and intracellular activity of ketolide HMR 3647 in human phagocytic and nonphagocytic cells. Clin Microbiol Infect (2001) 7(2):65-69.
  48. Bosnar M, Kelneric Z, Munic V, Erakovic V, Parnham MJ: Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin and cethromycin. Antimicrob Agents Chemother (2005) 49(6):2372-2377.
    • Містить порівняння клітинного накопичення макролідів.
  49. Pastan I, Willingham MC: The pathway of endocytosis. In: Endocytosis. Plenum Press, New York, NY, USA (1985):1-44.
  50. Nagai J, Takano M: Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet (2004) 19(3):159-170.
  51. Van Bambeke F, Carryn S, Seral C, Chanteux H, Tyteca D, MingeotLeclercq MP, Tulkens PM: Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother (2004) 48(8):2853-2860.
  52. Bulgheroni A, Jabes D, Pollini W, Carrano L, Desperati V, Romagnoli M, Rovida C, Colombo M, Garofalo F: Dalbavancin (DAL) uptake by murine macrophages. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (2004):A1490.
  53. Barcia-Macay M, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F: Telavancin (TEL) accumulates in cultured macrophages and is active against intracellular S aureus. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (2005):A-1831.
  54. Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH: Differential recognition of β-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem (1995) 270(43):25672-25677.
  55. Luckner P, Brandsch M: Interaction of 31 β-lactam antibiotics with the H+/peptide symporter PEPT2: Analysis of affinity constants and comparison with PEPT1. Eur J Pharm Biopharm (2005) 59(1):17-24.
  56. Li YH, Tanno M, Itoh T, Yamada H: Role of the monocarboxylic acid transport system in the intestinal absorption of an orally active β-lactam prodrug: Carindacillin as a model. Int J Pharm (1999) 191(2):151-159.
  57. Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V: β-Lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem (2000) 275(3):1699-1707.
  58. Bounds SJ, Nakkula R, Walters JD: Fluoroquinolone transport by human monocytes: Characterization and comparison to other cells of myeloid lineage. Antimicrob Agents Chemother (2000) 44(10):2609-2614.
  59. Van Bambeke F, Balzi E, Tulkens PM: Antibiotic efflux pumps. Biochem Pharmacol (2000) 60(4):457-470.
  60. Van Bambeke F, Michot JM, Tulkens PM: Antibiotic efflux pumps in eukaryotic cells: Occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J Antimicrob Chemother (2003) 51(5):1067-1077.
  61. Nichterlein T, Kretschmar M, Schadt A, Meyer A, Wildfeuer A, Laufen H, Hof H: Reduced intracellular activity of antibiotics against Listeria monocytogenes in multidrug resistant cells. Int J Antimicrob Agents (1998) 10(2):119-125.
  62. Leslie EM, Deeley RG, Cole SP: Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2 and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol (2005) 204(3):216-237.
  63. Sugiyama Y, Kusuhara H, Suzuki H: Kinetic and biochemical analysis of carrier-mediated efflux of drugs through the blood-brain and blood-cerebrospinal fluid barriers: Importance in the drug delivery to the brain. J Control Release (1999) 62(1-2):179-186.
  64. Inui KI, Masuda S, Saito H: Cellular and molecular aspects of drug transport in the kidney. Kidney Int (2000) 58(3):944-958.
  65. Hand WL, King-Thompson NL: Membrane transport of clindamycin in alveolar macrophages. Antimicrob Agents Chemother (1982) 21(2):241-247.
  66. Hand WL, Corwin RW, Steinberg TH, Grossman GD: Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis (1984) 129(6):933-937.
  67. Darouiche RO, Hamill RJ: Antibiotic penetration of and bactericidal activity within endothelial cells. Antimicrob Agents Chemother (1994) 38(5):1059-1064.
  68. Ulrich M, Albers C, Moller JG, Dalhoff A, Korfmann G, Kunkele F, Doring G: Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against Streptococcus pneumoniae in vitro when administered up to 6 hours after challenge. Antimicrob Agents Chemother (2005) 49(12):5119-5122.
  69. Baltch AL, Bopp LH, Smith RP, Michelsen PB, Ritz WJ: Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes. J Antimicrob Chemother (2005) 56(1):104-109.
  70. Smith RP, Baltch AL, Franke MA, Michelsen PB, Bopp LH: Levofloxacin penetrates human monocytes and enhances
    intracellular killing of Staphylococcus aureus and Pseudomonas aeruginosa. J Antimicrob Chemother (2000) 45(4):483-488.
  71. Eick S, Pfister W: Efficacy of antibiotics against periodontopathogenic bacteria within epithelial cells: An in vitro study. J Periodontol (2004) 75(10):1327-1334.
  72. Scaglione F, Demartini G, Dugnani S, Fraschini F: A new model examining intracellular and extracellular activity of amoxicillin, azithromycin and clarithromycin in infected cells. Chemotherapy (1993) 39(6):416-423.
  73. Chiu CH, Lin TY, Ou JT: In vitro evaluation of intracellular activity of antibiotics against non-typhoid Salmonella. Int J Antimicrob Agents (1999) 12(1):47-52.
  74. Edelstein PH, Edelstein MA: In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species. Antimicrob Agents Chemother (1994) 38(2):200-204.
  75. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM: Activity of three β-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J Antimicrob Chemother (2005) 55(6):897-904.
    • Містить демонстрацію непередбаченої внутрішньоклітинної активності β-лактамів.
  76. Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F: Pharmacodynamic evaluation of the intracellular activity of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother (2006) 50(3):841-851.
    •• Містить порівняння клітинної фармакокінетики та фармакодинаміки антибіотиків проти S. aureus в якості моделі фаголізосомальної інфекції.
  77. Fitzgerald D, Haas DW: Mycobacterium tuberculosis. In: Principles and Practice of Infectious Diseases. Mandell GL, Bennet JE, Dolin R (Eds), Elsevier Churchill Livingstone, Philadelphia, PA, USA (2005):2852-2886.
  78. Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM: Comparative intracellular (THP-1 macrophage) and extracellular activities of β-lactams, azithromycin, gentamicin and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob Agents Chemother (2002) 46(7):2095-2103.
    •• Містить порівняння активності антибіотиків проти L. monocytogenes в якості моделі цитозольної інфекції.
  79. Hand WL, King-Thompson NL: Contrasts between phagocyte antibiotic uptake and subsequent intracellular bactericidal activity. Antimicrob Agents Chemother (1986) 29(1):135-140.
  80. Seral C, Barcia-Macay M, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F: Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J Antimicrob Chemother (2005) 55(4):511-517.
  81. Scaglione F: Predicting the clinical efficacy of antibiotics: Toward definitive criteria. Pediatr Infect Dis J (1997) 16(3 Suppl):S56-S59.
  82. Aubert-Tulkens G, Van Hoof F, Tulkens P: Gentamicin-induced lysosomal phospholipidosis in cultured rat fibroblasts. Quantitative ultrastructural and biochemical study. Lab Invest (1979) 40(4):481-491.
  83. Van Bambeke F, Saffran J, Mingeot-Leclercq MP, Tulkens PM: Mixedlipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob Agents Chemother (2005) 49(5):1695-1700.
  84. Ouadrhiri Y, Scorneaux B, Sibille Y, Tulkens PM: Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by γ interferon. Antimicrob Agents Chemother (1999) 43(5):1242-1251.
  85. Van de Velde S, Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM: Increased susceptibility of intracellular Listeria monocytogenes to ampicillin: Studies with Caco-2 cells and THP-1 macrophages. 15th International Symposium on Problems of Listeriosis (ISOPOL), Uppsala, Sweden (2004):P123.
  86. Gouin E, Welch MD, Cossart P: Actin-based motility of intracellular pathogens. Curr Opin Microbiol (2005) 8(1):35-45.
  87. Portnoy DA, Auerbuch V, Glomski IJ: The cell biology of Listeria monocytogenes infection: The intersection of bacterial pathogenesis and cell-mediated immunity. J Cell Biol (2002) 158(3):409-414.
  88. Duclos S, Desjardins M: Subversion of a young phagosome: The survival strategies of intracellular pathogens. Cell Microbiol (2000) 2(5):365-377.
  89. Fisher MA, Plikaytis BB, Shinnick TM: Microarray analysis of the Mycobacterium tuberculosis transcriptional response to the acidic conditions found in phagosomes. J Bacteriol (2002) 184(14):4025-4032.
  90. Weinrick B, Dunman PM, McAleese F, Murphy E, Projan SJ, Fang Y, Novick RP: Effect of mild acid on gene expression in Staphylococcus aureus. J Bacteriol (2004) 186(24):8407-8423.
  91. Nicholson TL, Olinger L, Chong K, Schoolnik G, Stephens RS: Global stage-specific gene regulation during the developmental cycle of Chlamydia trachomatis. J Bacteriol (2003) 185(10):3179-3189.
  92. Tierrez A, Garcia-del Portillo F: New concepts in Salmonella virulence: The importance of reducing the intracellular growth rate in the host. Cell Microbiol (2005) 7(7):901-909.
  93. Theus SA, Cave MD, Eisenach KD: Intracellular macrophage growth rates and cytokine profiles of Mycobacterium tuberculosis strains with different transmission dynamics. J Infect Dis (2005) 191(3):453-460.
  94. Seral C, Van Bambeke F, Tulkens PM: Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin,
    moxifloxacin and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother (2003) 47(7):2283-2292.
  95. Siewert K, Rupp J, Klinger M, Solbach W, Gieffers J: Growth cycledependent pharmacodynamics of antichlamydial drugs. Antimicrob Agents Chemother (2005) 49(5):1852-1856.
  96. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Glupzynski Y, Tulkens PM: Carbapenems (ETP, MEM) are active against intraphagocytic MRSA in a THP-1 macrophage model. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA (2005):A1832.
  97. Sabath LD, Wallace SJ, Gerstein DA: Suppression of intrinsic resistance to methicillin and other penicillins in Staphylococcus aureus. Antimicrob Agents Chemother (1972) 2(5):350-355.
  98. Van Bambeke F, Glupzynski Y, Plesiat P, Pechere JC, Tulkens PM: Antibiotic efflux pumps in prokaryotic cells: Occurrence, impact for resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother (2003) 51(5):1167-1173.
  99. Hirakata Y, Srikumar R, Poole K, Gotoh N, Suematsu T, Kohno S, Kamihira S, Hancock RE, Speert DP: Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa. J Exp Med (2002) 196(1):109-118.
  100. Thanassi DG, Cheng LW, Nikaido H: Active efflux of bile salts by Escherichia coli. J Bacteriol (1997) 179(8):2512-2518.
  101. Prior S, Gander B, Blarer N, Merkle HP, Subira ML, Irache JM, Gamazo C: In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur J Pharm Sci (2002) 15(2):197-207.
  102. Prior S, Gander B, Lecaroz C, Irache JM, Gamazo C: Gentamicinloaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes. J Antimicrob Chemother (2004) 53(6):981-988.
  103. Makino K, Nakajima T, Shikamura M, Ito F, Ando S, Kochi C, Inagawa H, Soma G, Terada H: Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: Effects of molecular weight and composition of PLGA on release of rifampicin. Colloids Surf B Biointerfaces (2004) 36(1):35-42.
  104. Rudin DE, Gao PX, Cao CX, Neu HC, Silverstein SC: Gemfibrozil enhances the listeriacidal effects of fluoroquinolone antibiotics in J774 macrophages. J Exp Med (1992) 176(5):1439-1447.
  105. Seral C, Carryn S, Tulkens PM, Van Bambeke F: Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. J Antimicrob Chemother (2003) 51(5):1167-1173.
  106. Mandell GL, Coleman EJ: Activities of antimicrobial agents against intracellular pneumococci. Antimicrob Agents Chemother (2000) 44(9):2561-2563.
  107. Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM: Activity of β-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model. J Antimicrob Chemother (2003) 51(4):1051-1052.
  108. Duman N, Cevikbas A, Johansson C: The effects of rifampicin and fluoroquinolones on tubercle bacilli within human macrophages. Int J Antimicrob Agents (2004) 23(1):84-87.
  109. Takemura H, Yamamoto H, Kunishima H, Ikejima H, Hara T, Kanemitsu K, Terakubo S, Shoji Y, Kaku M, Shimada J: Evaluation of a human monocytic cell line THP-1 model for assay of the intracellular activities of antimicrobial agents against Legionella pneumophila. J Antimicrob Chemother (2000) 46(4):589-594.
  110. Sikri V, Pal D, Jain R, Kalyani D, Mitra AK: Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing Pglycoprotein efflux. Am J Ther (2004) 11(6):433-442.
  111. Bamberger DM, Herndon BL, Dew M, Chern RP, Mitchell H, Summers LE, Marcus RF, Kim SC, Suvarna PR: Efficacies of ofloxacin, rifampin and clindamycin in treatment of Staphylococcus aureus abscesses and correlation with results of an in vitro assay of intracellular bacterial killing. Antimicrob Agents Chemother (1997) 41(5):1178-1181.
  112. Nielsen SL, Black FT: Extracellular and intracellular killing in neutrophil granulocytes of Staphylococcus aureus with rifampicin in combination with dicloxacillin or fusidic acid. J Antimicrob Chemother (1999) 43(3):407-410.
  113. Michelet C, Avril JL, Arvieux C, Jacquelinet C, Vu N, Cartier F: Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprim-sulfamethoxazole or rifampin, against intracellular Listeria monocytogenes. Antimicrob Agents Chemother (1997) 41(1):60-65.
  114. Gumbo T, Louie A, Deziel MR, Drusano GL: Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother (2005) 49(8):3178-3181.
  115. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL: Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis (2004) 190(9):1642-1651.
    •• Описано використання математичного моделювання та фармакодинамічних концепцій для встановлення відповідного дозування хінолону проти мікобактерій.
  116. Alferova IV, Vostrov SN, Portnoy YA, Lubenko IY, Zinner SH, Firsov AA: Comparative pharmacodynamics of telithromycin and clarithromycin with Streptococcus pneumoniae and Staphylococcus aureus in an in vitro dynamic model: Focus on clinically achievable antibiotic concentrations. Int J Antimicrob Agents (2005) 26(3):197-204.
  117. Tano E, Cars O, Lowdin E: Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model. J Antimicrob Chemother (2005) 56(1):240-242.
    •• Описано першу динамічну модель in vitro для оцінки внутрішньоклітинної активності антибіотиків.
  118. Roch N, Maurin M: Antibiotic susceptibilities of Legionella pneumophila strain Paris in THP-1 cells as determined by real-time PCR assay. J Antimicrob Chemother (2005) 55(6):866-871.
    •• Описано швидке кількісне визначення внутрішньоклітинних бактерій за допомогою ПЛР у реальному часі.
  119. Qazi SN, Harrison SE, Self T, Williams P, Hill PJ: Real-time monitoring of intracellular Staphylococcus aureus replication. J Bacteriol (2004) 186(4):1065-1077.
    •• Описано метод розрізнення життєздатних і нежиттєздатних внутрішньоклітинних бактерій за допомогою флуоресцентних і фосфоресцентних зондів.
  120. Malouin F, Brouillette E, Martinez A, Boyll BJ, Toth JL, Gage JL, Allen NE: Identification of antimicrobial compounds active against intracellular Staphylococcus aureus. FEMS Immunol Med Microbiol (2005) 45(2):245-252.
  121. Takii T, Hamasaki S, Hirano K, Abe C, Onozaki K: Simple fibroblastbased assay to test the pyrazinamide susceptibility of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 49(2):804-807.
  122. Cuffini AM, Tullio V, Bonino A, Allocco A, Palarchio AI, Carlone NA: Entry of sanfetrinem into human polymorphonuclear granulocytes and its cell-associated activity against intracellular, penicillinresistant Streptococcus pneumoniae. Antimicrob Agents Chemother (1998) 42(7):1745-1750.
  123. Edelstein PH, Hu B, Edelstein MA: In vitro and intracellular activities of LBM415 (NVP PDF-713) against Legionella pneumophila. Antimicrob Agents Chemother (2005) 49(6):2533-2535.
  124. Gustafsson I, Engstrand L, Cars O: In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori. Antimicrob Agents Chemother (2001) 45(1):353-355.
  125. Ordway D, Viveiros M, Leandro C, Arroz MJ, Amaral L: Intracellular activity of clinical concentrations of phenothiazines including thioridiazine against phagocytosed Staphylococcus aureus. Int J Antimicrob Agents (2002) 20(1):34-43.
  126. Edelstein PH, Weiss WJ, Edelstein MA: Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L pneumophila pneumonia. Antimicrob Agents Chemother (2003) 47(2):533-540.
  127. Brouillette E, Grondin G, Lefebvre C, Talbot BG, Malouin F: Mouse mastitis model of infection for antimicrobial compound efficacy studies against intracellular and extracellular forms of Staphylococcus aureus. Vet Microbiol (2004) 101(4):253-262.
  128. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V: Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother (2003) 47(7):2118-2124.
  129. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC: Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother (2005) 49(7):2816-2821.
  130. Langer O, Karch R, Muller U, Dobrozemsky G, Abrahim A, Zeitlinger M, Lackner E, Joukhadar C, Dudczak R, Kletter K, Muller M et al: Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans. J Nucl Med (2005) 46(11):1835-1841.
    • Описано неінвазивний метод вимірювання внутрішньоклітинної концентрації антибіотиків in vivo.
  131. Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, Gorman G, Nikonenko B, Protopopova M: Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol (2005) 144(1):80-87.
  132. Michelet C, Leib SL, Bentue-Ferrer D, Tauber MG: Comparative efficacies of antibiotics in a rat model of meningoencephalitis due to Listeria monocytogenes. Antimicrob Agents Chemother (1999) 43(7):1651-1656.
  133. Prior S, Gander B, Irache JM, Gamazo C: Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice. J Antimicrob Chemother (2005) 55(6):1032-1036.
Сторінки: 1 2

Залишити коментар